ACIP Recommends Delaying newborn Hepatitis B Vaccine, raising Public Health Concerns
A shift in vaccination policy could lead to increased cases of hepatitis B in infants, as the US Advisory Committee on Immunization Practices (ACIP) voted 8 to 3 to recommend delaying the hepatitis B virus (HBV) vaccine for newborns. The new recommendation suggests administering the vaccine to children born to HBV-negative mothers beginning at two months of age, a departure from the previous worldwide vaccination within 24 hours of birth. While the Centers for Disease Control and Prevention (CDC) has not yet officially adopted the recommendation, pending a decision by the CDC director, experts warn of potential consequences.
Hepatitis B: A Silent Threat
HBV is a highly contagious virus transmitted through infected blood and body fluids, capable of surviving on contaminated surfaces for up to seven days. An initial acute hepatitis B infection, lasting less than six months, can resolve on its own. However, if the virus persists beyond this timeframe, it develops into chronic hepatitis B (CHB), a lifelong condition that substantially elevates the risk of severe complications like liver cirrhosis and hepatocellular carcinoma.
The severity of the situation is compounded by the widespread underdiagnosis of CHB. According to data from GlobalData, as of 2024, only 59% of individuals with CHB in the US are aware of their infection status. This low rate is largely attributed to the virus’s often asymptomatic nature. While some newly infected individuals may experience symptoms such as fatigue, poor appetite, stomach pain, nausea, and jaundice, many remain unaware they are carriers.
Vulnerable Infants at Risk
Despite CDC recommendations for HBV testing during pregnancy, some women remain undiagnosed, leaving their newborns vulnerable. The risk of CHB infection in infants born to HBV-infected mothers is approximately 90%, highlighting the critical importance of preventative measures in this population. “This particular population of patients is crucial for preventing long-term infection and complications,” one analyst noted.
Global Efforts contradicted
The ACIP’s recommendation stands in direct contrast to the World Health Organization’s (WHO) global strategy for eliminating viral hepatitis. The WHO advocates for universal HBV birth dose vaccination policies as a crucial safety net, protecting all newborns regardless of their mother’s HBV status. according to the WHO, over 80% of individuals globally living with hepatitis B are unaware of their diagnosis, underscoring the need for proactive prevention.
Key opinion leaders emphasize the urgent need for increased screening and awareness of preventative measures, including vaccinations. The delay in the US, sadly, is predicted to lead to an increase in paediatric cases of hepatitis B and exacerbate the existing public health challenge of underdiagnosis.
Why: the US Advisory Committee on Immunization Practices (ACIP) voted to recommend delaying the HBV vaccine for newborns born to HBV-negative mothers, shifting from universal vaccination at birth to administration at two months of age.
Who: The decision was made by the ACIP, with a vote of 8 to 3. The CDC director will ultimately decide whether to adopt the recommendation. The policy impacts all newborns in the US, notably those born to mothers who are not known to have HBV.
What: The change involves delaying the first dose of the HBV vaccine for infants born to mothers who test negative for the virus. Previously, all newborns received the
